UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 15, 2011
Impax Laboratories, Inc.
 (Exact name of registrant as specified in its charter)

Delaware	 	001-34263	 	65-0403311	
(State or other Jurisdiction of Incorporation)	 	(Commission File Number)	 	(IRS Employer Identification No.)	
 	 	 	
30831 Huntwood Avenue, Hayward, CA	 	94544	
(Address of Principal Executive Offices)	 	(Zip Code)	
Registrant’s telephone number, including area code: (510) 476-2000

Not Applicable	
(Former name or former address if changed since last report.)	
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 15, 2011, Charles V. Hildenbrand, Senior Vice President, Operations, informed Impax Laboratories, Inc. (the “Company”) of his intent to resign effective June 17, 2011. The Company is currently aggressively seeking a new executive with experience in pharmaceutical manufacturing and operations. On an interim basis, Mr. Hildenbrand’s responsibilities will be assumed by the Chief Executive Officer of the Company.
1

 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 16, 2011
IMPAX LABORATORIES, INC .
By: /s/ Arthur A. Koch, Jr.                                      
Name: Arthur A. Koch, Jr.
Title: Executive Vice President, Finance, and
Chief Financial Officer
2